Drug Type Small molecule drug |
Synonyms SLC 0111, WBI-5111 |
Target |
Mechanism CAIX inhibitors(Carbonic anhydrase IX inhibitors) |
Active Indication |
Inactive Indication |
Originator Organization |
Active Organization |
Inactive Organization |
Drug Highest PhasePhase 1/2 |
First Approval Date- |
Regulation- |
Molecular FormulaC13H12FN3O3S |
InChIKeyYJQZNWPYLCNRLP-UHFFFAOYSA-N |
CAS Registry178606-66-1 |
Indication | Highest Phase | Country/Location | Organization | Date |
---|---|---|---|---|
Pancreatic Cancer | Phase 2 | - | 29 Jan 2024 | |
Metastatic Pancreatic Ductal Adenocarcinoma | Phase 2 | CA | 10 Jan 2019 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CA | 01 Oct 2014 | |
Advanced Malignant Solid Neoplasm | Phase 1 | CA | 01 Oct 2014 |
Phase 1 | - | vlhuirwewp(ziunsqqtdg) = dosed at ≤1000 mg with fewer TRAE ≥ grade 3 and fewer AEs such as nausea and vomiting, compared with the 2000-mg cohort jnrahxndfz (mkcahutyyr ) View more | Positive | 01 Jul 2020 |